Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Phil Cressman who wrote (29873)	1/4/2000 6:28:00 PM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

Yes, this announcement was unexpected and further demonstrates the power of their technology. Partners have now put 6 compounds into trials (AHP - TSE424, ERA923, WAY160910 ; PFE - Droloxifene and Lasofoxifene ; GLX - GW544). In addition, LGND has FDA approvals on three drugs this year (Topical Panretin, ONTAK, Oral Targretin), a Biotech record, an NDA filed on another (Topical Targretin), another finishing Phase III trials (Oral Panretin), and another in trials LGD1550. It's easy to see why many consider LGND's pipeline the best in the business and it's also easy to understand why CEO Robinson says 2000 is going to be a very good year for LGND.